First-in-human Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults (clinicaltrials.gov) - Aug 18, 2025 - P1 | N=192 | Recruiting | Sponsor: Clover Biopharmaceuticals AUS Pty | Not yet recruiting ➔ Recruiting
Enrollment open • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections
|